Capecitabine for Metastatic Renal Cell Carcinoma
Author Information
Author(s): Oevermann K, Buer J, Hoffmann R, Franzke A, Schrader A, Patzelt T, Kirchner H, Atzpodien J
Primary Institution: Medizinische Hochshule Hannover
Hypothesis
The study evaluates the therapeutic effects and systemic toxicities of a capecitabine-based home therapy regimen in patients with metastatic renal cell carcinoma.
Conclusion
Capecitabine showed significant anti-tumor activity and was well tolerated in patients with advanced renal cell carcinoma.
Supporting Evidence
- There were two complete responses and eight partial remissions.
- The overall objective response rate was 34%.
- Capecitabine-related toxicities were mostly grade 2 and 3.
Takeaway
Doctors tested a new medicine called capecitabine on 30 patients with kidney cancer, and it helped some of them feel better without making them too sick.
Methodology
A phase II clinical trial with oral capecitabine combined with other treatments.
Limitations
The study had a small sample size and was limited to outpatient therapy.
Participant Demographics
Patients with metastatic renal cell carcinoma.
Statistical Information
Confidence Interval
95% CI 17–53%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website